Please login to the form below

Onpattro

This page shows the latest Onpattro news and features for those working in and with pharma, biotech and healthcare.

for standard of care Onpattro (patisiran), Alnylam’s earlier RNAi ATTRv amyloidosis therapy that is administered intravenously every few weeks.

AstraZeneca and Ionis sign $3.6bn deal for eplontersen

However, if approved, eplontersen will not have the ATTR market to itself and must compete with Pfizer’s Vyndaqel/Vyndamax (tafamidis) and Alnylam’s RNAi therapy Onpattro (patisiran).
Novo Nordisk signs deal for Prothena's heart drug worth up to $1.2bn

Elsewhere in the therapy area is Alnylam’s Onpattro (patisiran), which received approval in hereditary ATTR amyloidosis (hATTR) in 2018. ... Onpattro is also currently being evaluated in a phase 3 study in ATTR amyloidosis with cardiomyopathy, with
Alnylam scores EU approval for RNAi drug Givlaari

Alnylam’s first RNAi drug – Onpattro (patisiran) for rare disease hereditary ATTR amyloidosis – has a similar pricing strategy. ... Onpattro, on the other hand, launched with a $450, 000 per year price tag, and subsequently dropped to $345, 000
Pfizer’s Vyndaqel is first EU therapy for ATTR cardiomyopathy

In the ATTR polyneuropathy indication it has competition from Alnylam’s injectable drugs Onpattro (patisiran) and Ionis’ Tegsedi (inotersen), which were approved for that use in Europe in 2018.
Alnylam’s third RNAi drug clears phase 3 trial in rare kidney disease

If approved, lumasiran would be Alnylam’s third RNAi drug after Onpattro (patisiran) for polyneuropathy in rare disease hereditary ATTR amyloidosis, which was cleared by the FDA in 2018, and Givlaari

More from news
Approximately 7 fully matching, plus 15 partially matching documents found.

20 for 2020 – Five pharma leaders to watch in 2020

Onpattro was approved to treat adults with the. destruction of nerves that results from a rare disease, hereditary transthyretin- mediated (hATTR) amyloidosis, and was launched with a $450, 000 per year ... The company has tried to be creative with its
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

Alnylam's Theresa Heggie. Alnylam and its extraordinary ‘gene silencing’ technology is making its debut in Europe with the launch of Onpattro. ... PME talks to its European leader Theresa Heggie. Even as it launches its first ever product Onpattro,

More from intelligence
Approximately 1 fully matching, plus 1 partially matching documents found.

Account Manager, Healthcare Marketing Creative Agency, Fixed ter...: Highly competitive salary

Senior Medical Copywriter - Highly Awarded Advertising Agency: £50,000 - £60,000 yearly

Account Manager, 6 month contract, Healthcare Brand communicatio...: Highly competitive salary

Home Based Account Manager, Medical Communications, UK, Pharma/M...: Highly competitive salary

Market Access Director, six figure base salary and £5K joining b...: Highly competitive salary

Account Director, Healthcare Marketing Creative Agency, Fixed te...: Highly competitive salary

No results were found

Add my company

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Tuberculosis – why it remains a major global public health challenge: Innovative collaboration is required to address the major public health challenges around TB and expedite drug development...
Whitepaper: Closing the gap with compelling healthcare communications: Want to learn how to close the distance between a person’s current health and their healthiest possible self?...
Healing the Healers: Because if we do not heal the healers, who is going to heal us?...

Email:
Password: